Adequacy of Olmesartan monotherapy versus cotherapy in patients with essential hypertension

Abstract

Olmesartan is a class of an angiotensin II receptor blocker drugs used for the treatment of hypertension. The aim of this crossover clinical study is to evaluate the safety and effectiveness of Olmesartan monotherapy compared to Olmesartan plus amlodipine co-therapy in patients with essential hypertension. An entire of eighty-three patients (45 males, 38 females) their age ranging (45-55 ) years with essential hypertension enrolled from Al Yarmouk hospital /Iraq for this study. After reaching the point of inclusion criteria, they treated with Olmesartan medoxomil 20 mg daily for a period of two months, then after two weeks of wash off, they treated with Olmesartan 20 mg daily plus amlodipine 10 mg daily for another two months.Blood pressure (systolic and diastolic) and clinical laboratory tests that include fasting blood levels of glucose, insulin, lipid profile, adiponectin, leptin, cystatin c and creatinine were obtained and studied at baseline (prior treatment), after two months of Olmesartan monotherapy and after two months of Olmesartan co-therapy.The statistical analyses of the data in patients using Olmesartan co-therapy versus Olmesartan mono therapy showed more effectiveness in decreasing blood pressure, better in reducing the blood levels of glucose, insulin, total cholesterol, triglyceride, and leptin, superior in elevating the values of insulin sensitivity index and in elevating the blood levels of adiponectin. Concisely, the addition of amlodipine to Olmesartan treatment ameliorated insulin sensitivity and adiponectin level and attenuated the leptin level.